IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
نویسندگان
چکیده
منابع مشابه
Management of Moderate to Severe Plaque Psoriasis
cancer, arthritis, hypertension, heart disease, diabetes, and depression (Rapp 1999). In the last decade, a new understanding about the pathophysiology of psoriasis has resulted in the development of a new class of agents for these patients: targeted biologic therapy. These novel treatments target specific immunologic processes involved in the genesis of this disease, providing significant clin...
متن کاملA Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Brodalumab is highly effective in the reversal of psoriatic phenotype and gene expression patterns.
متن کاملApremilast in the treatment of moderate-to-severe plaque psoriasis:
2015 Psoriasis is a chronic, systemic inflammatory disease that often has a negative impact on daily functioning and quality of life. Although many treatment options are available, patients are often dissatisfied with their current disease management. Apremilast, an oral PDE4 inhibitor, was recently approved in multiple countries for the treatment of patients with active psoriatic arthritis and...
متن کاملMethotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
BACKGROUND Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe chronic plaque psoriasis. We conducted a randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life. METHODS A total of 88 patients with moderate-to-severe psoriasis were randomly assigned to treatment for 16 weeks with ei...
متن کاملA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
• Interleukin (IL)-23 and IL-17 play an important role in the development of psoriasis. • Many of the new biologic drugs targeting IL-23 and IL-17 have been shown to be both safe and effective in treating moderate-to-severe plaque psoriasis. Long-term safety data still need to be established. • These drugs are more selective with inhibition of " downstream " targets in the immunopathogenesis of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Immunology
سال: 2019
ISSN: 1664-3224
DOI: 10.3389/fimmu.2019.01865